SABCS 2023 Highlights Open the Door for More Key Data in 2024

— Virginia Kaklamani, MD, discusses this year’s sessions of hobby and appears forward to subsequent year

by
Greg Laub, Director, Video, MedPage This day
December 22, 2023

In this outlandish MedPage This day video, Virginia Kaklamani, MD, DSc, of UT Health Sciences Heart in San Antonio and co-director of the San Antonio Breast Most cancers Symposium (SABCS), highlights just some of the most impactful and paradigm-shifting sessions in breast cancer presented at this year’s symposium — and provides some insight into what questions will be answered in the subsequent year.

The next is a transcript of her remarks:

This year has been the forty sixth year of having the symposium. The symposium started as a tiny meeting of 30 physicians, largely a tumor board between experts and local physicians in San Antonio. It then grew into the most attention-grabbing symposium of breast cancer in the area. We possess researchers from in each place the area — nearly a hundred worldwide locations — coming right here and in fact sharing their views, exchanging suggestions, and searching for to pass the sphere forward.

The symposium this year had several sessions that I bellow are severe. We had a prevention session. We had a lobular carcinoma session and an inflammatory breast cancer session. It furthermore had loads of files on local therapy, largely how to de-escalate our therapy, how to not give radiation if we build not need to, how to not produce axillary node dissection if we build not need to. And this in fact improves the morbidity of our sufferers.

And it furthermore had in fact fascinating files on aggregate therapy such because the INAVO120 trial, looking at aggregate of a PI3 kinase inhibitor, a CDK4/6 inhibitor and endocrine therapy, and furthermore our HER2CLIMB-02 trial, looking at a aggregate of T-DM1 [trastuzumab emtansine, Kadcyla] and tucatinib [Tukysa] in sufferers with metastatic HER2-clear breast cancer. So I bellow design Monday morning, we’re going to be altering our discover quite quite in step with the details that used to be presented this year at SABCS.

So 2024, we’re going to possess some answers to several key questions. The essential query is, produce we sequence CDK4/6 inhibitors? End we give a CDK4/6 inhibitor, and at disease progression give one other one? And we’re going to possess answers from the postMONARCH trial, which would be going to all as soon as more alternate our same outdated of care.

We’re furthermore going to possess some files on varied oral SERDs [selective estrogen receptor degraders]. This year we had the approval of elacestrant [Orserdu] in step with scientific trial files, suggesting that it be active in tumors which possess ESR1 mutations. Subsequent year we’re going to possess some files from two varied oral SERDs — imlunestrant and camizestrant — in aggregate with varied treatments. So I bellow that’ll be gorgeous fascinating and hopefully more drug approvals for our sufferers.

After which we had some files this year looking at immunotherapy in a excessive-probability hormone receptor-clear early stage breast cancer. However I bellow it may maybe maybe be needed to investigate cross-check what subset, molecular subset of sufferers rep loads of the encourage. So right here’s one thing that I bellow is going to be explored subsequent year.

After which we’re going to possess some readouts in triple-destructive breast cancer trials — all as soon as more, looking at tweaking of immunotherapy and antibody drug conjugates which had been in fact the substantial memoir for the final 2 or 3 years — are going to continue to present us files and hopefully present us more agents, more active agents for our sufferers.